Welcome to
Together is a new resource for anyone affected by pediatric cancer - patients and their parents, family members, and friends.
Learn MoreTargeted Therapy
Other names:
AZD6244
Often used for:
Neurofibromatosis type 1 (NF1)
Selumetinib (MEK inhibitor AZD6244) is a type of medicine called a targeted therapy. Selumetinib acts to block certain cell signals that may help keep cancer cells from growing.
Selumetinib is an investigational drug being studied for several types of cancers. Patients will have regular blood draws to check blood counts and to monitor liver and kidney function. Because selumetinib is a new drug, patients will be monitored closely as part of a clinical trial.
Given as a capsule by mouth
Not all patients who take selumetinib will experience these side effects. Common side effects are in bold, but there may be others. Please report all suspected side effects to your doctor or pharmacist.
Be sure to discuss these and other recommendations with your doctor or pharmacist.